Resveratrol treatment in older glucose-intolerant adults improved fasting reactive hyperemia index (2.02 vs 1.76, p=0.002) but did not change glucose metabolism or insulin sensitivity.
RCT (n=30)
crossover
double-blind
glucose intolerance (n=30)
resveratrol vs placebo (2-3 g/daily)
fasting reactive hyperemia index, p=.002
Absolute Event Rate: 2.02% vs 1.76%
p-value: p=.002
BACKGROUND: Resveratrol, a plant-derived polyphenol, has been reported to improve glucose metabolism and vascular function and to extend life span in animal models, but studies in humans have been inconclusive. METHODS: In a randomized, double-blind crossover study, we treated older glucose-intolerant adults (n = 30) with resveratrol (2-3 g/daily) or placebo, each for 6 weeks. A standard mixed-meal test was used to assess insulin sensitivity (Matsuda index) and secretion (C-peptide deconvolution) and vascular function by reactive hyperemia peripheral arterial tonometry. Skeletal muscle samples were obtained for gene expression using RNA-Seq analysis and to assess mitochondrial morphology. RESULTS: There were no changes in glucose tolerance, insulin sensitivity, weight, blood pressure, or lipid profile following resveratrol treatment. Fasting reactive hyperemia index improved with resveratrol (2.02 ± 0.2 vs 1.76 ± 0.02, p = .002). RNA-Seq analysis yielded 140 differentially expressed transcripts (corrected p-value ≤ .05), predominantly associated with mitochondrial genes and noncoding RNA. Ingenuity Pathway Analysis confirmed that mitochondrial dysfunction (p = 2.77 × 10-12) and oxidative phosphorylation (p = 1.41 × 10-11) were the most significantly perturbed pathways. Mitochondrial number, but not size, was increased. CONCLUSIONS: Resveratrol treatment of older adults with impaired glucose regulation may have beneficial effects on vascular function, but not glucose metabolism or insulin sensitivity. Changes in gene expression suggest effects similar to those observed with caloric restriction, which has been shown to increase life and health span in animal models, although its significance for humans is uncertain. Future human studies should address the appropriate dose range and low bioavailability of resveratrol.
Building similarity graph...
Analyzing shared references across papers
Loading...
Rena Pollack
Hebrew University of Jerusalem
Nir Barzilai
Albert Einstein College of Medicine
Valentin Anghel
Albert Einstein College of Medicine
The Journals of Gerontology Series A
Harvard University
Stanford University
Albert Einstein College of Medicine
Building similarity graph...
Analyzing shared references across papers
Loading...
Pollack et al. (Thu,) conducted a rct in glucose intolerance (n=30). resveratrol vs. placebo was evaluated on fasting reactive hyperemia index (p=.002). Resveratrol treatment in older glucose-intolerant adults improved fasting reactive hyperemia index (2.02 vs 1.76, p=0.002) but did not change glucose metabolism or insulin sensitivity.
synapsesocial.com/papers/6a18115c4f2b3115b0135c8e — DOI: https://doi.org/10.1093/gerona/glx041